Nature of Disclosure & Key Updates

The disclosure is a transcript of the quarterly earnings conference call. Management highlighted a volatile operating environment due to geopolitical conflict in the Middle East, causing supply chain disruptions, elevated freight costs, longer transit times, and inflationary pressures.

Financial Performance for Q1 FY27 (Quarter Ended June 30, 2026)

  • Revenue: Reported ₹12.16 billion, representing a 13% year-on-year (YoY) growth.
  • Segment Performance:
  • US Revenue: Stood at ₹6,282 million ($68 million), described as stable.
  • Ex-US Revenue: Grew 17% YoY to ₹5,875 million ($63 million). This was lower than Q4 FY26's $70 million due to supply chain-related shipment delays, which are expected to be recovered in coming quarters.
  • Gross Profit: Gross margin expanded 60 basis points YoY to 60.9%. Absolute gross profit grew 14% YoY to ₹770.2 crore.
  • EBITDA: Reported at ₹229.8 crore, up 5.4% YoY. EBITDA margin was 18.2%, down 130 bps YoY but slightly above Q4 FY26's 18.1%. The company absorbed ₹13.1 crore in incremental operating and freight costs attributable to geopolitical disruptions.
  • Cost Breakdown:
  • Employee costs were steady at 19.2% of revenue.
  • Other operating costs (ex-freight) increased by ₹29.0 crore YoY due to higher manufacturing costs.
  • Freight costs increased to 6.2% of revenue from 5.3% a year ago, an increase of ₹18.9 crore.
  • Profit After Tax (PAT):
  • Operational PAT was ₹123.1 crore, up 8% YoY, with an EBITDA-to-PAT conversion of 54%.
  • Operational EPS was ₹13.4 per share, up 8% YoY.
  • Reported PAT was ₹165.5 crore, up 56.7% YoY.
  • Reported EPS was ₹17.0 per share.
  • Exceptional Item: The reported PAT includes a gain of ₹74.2 crore from divesting a majority stake in Pivot Path (a captive global capability centre), contributing ₹53.4 crore to PAT net of tax. The company retains a 20% stake.
  • Cash Flow & Working Capital:
  • Operating cash flow for the quarter was ₹108.7 crore, representing a 47% EBITDA-to-cash conversion.
  • The cash-to-cash cycle increased by 7 days YoY to 123 days, driven by a 24-day increase in inventory (to ensure supply chain resilience) and a 15-day increase in payable days.
  • Balance Sheet & Debt:
  • Net debt was reduced by ₹11.9 crore during the quarter to ₹1,424.6 crore.
  • Net debt-to-EBITDA ratio improved to 1.52x from 1.55x at FY26-end.
  • Net finance costs were ₹36.1 crore, compared to ₹40.6 crore in Q1 FY26.
  • The weighted average cost of debt was stated to be 7.6%.
  • Credit Rating: CARE Ratings upgraded the company's Long-Term Bank Facilities rating to 'CARE A+; Stable' from 'CARE A; Positive' during the quarter.
  • Returns: Return on Capital Employed (ROCE) on a trailing-twelve-month basis moderated to 15.3% from 15.8% in FY26.

Operational and Strategic Highlights

  • US Business:
  • Launched 2 products in the quarter, taking the total commercialized portfolio to 72 products.
  • Holds a top-three market position in 37 products, which contribute ~70% of US revenues.
  • Growth strategy is focused on profitability and niche domains: Controlled Substances, Nasal Sprays, Transdermal Patches, and Films. These are developed around the US manufacturing facility in Chestnut Ridge.
  • Nearly one-third of US revenues are supplied from the Chestnut Ridge facility.
  • Experienced delays in some product approvals, expected to materialize in coming quarters.
  • Management expects H2 FY27 to be stronger for the US business, supported by new approvals and launches.
  • The long-term aspiration is to build a $375 million North America business by FY28.
  • Ex-US Business:
  • Delivered strong growth across B2C markets (UK, Nordics, South Africa, Africa) and B2B markets (Europe, Australia).
  • The company is also developing newer regions: LATAM, MENA, and APAC, with revenues from these areas expected from FY28/29 onwards.
  • Management expects the Ex-US business to continue growing faster than the company average.
  • Product Pipeline:
  • Has over 100 products yet to be launched in the US.
  • In Nasal Sprays: One filing is in advanced stages of FDA review with approval expected in H2 FY27. A second product was filed recently, with a review expected to take 12-15 months. 5-6 more nasal spray programs are planned over the next 12-18 months.
  • Also focusing on filings for Transdermal Patches and Thin Films.
  • Targets 10 product launches for the remainder of FY27 (until March 31, 2027).
  • Controlled Substances:
  • Currently contributes ~5% to overall revenues.
  • The company has 4 products and has been demonstrating sales history for 20 months.
  • Quota allocations occur twice a year (June and December). Management expects to receive higher allocations in the next cycles to drive future growth.
  • ESG: The company's EcoVadis sustainability score improved to 68/100, a 19-point improvement YoY.
  • Capex: Annual capital expenditure (including maintenance capex and R&D) is guided to be in the range of ₹2.5 to ₹3.0 billion. There are no greenfield capex plans.
  • Regulatory Update: The Bangalore plant underwent a USFDA inspection in May 2026. The company has responded to the observations and awaits a reply from the USFDA by end-August or September 2026. No impact on current supplies is anticipated.

Guidance & Outlook

  • Gross Margin: Objective is to maintain gross margins within the 58% to 60% range.
  • Growth: Expects H2 FY27 to be stronger than H1, supported by new product approvals and launches.
  • Ex-US: Underlying demand remains healthy; expects to recover the Q4 FY26 spillover business in coming quarters.
  • Sandoz Acquisition: The acquisition of certain assets is not yet reflected in numbers. It is expected to close in Q2 FY27 and start contributing in H2 FY27.